KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Cvs Health (CVS) over the last 17 years, with Q4 2025 value amounting to -$2.0 billion.

  • Cvs Health's Cash from Financing Activities fell 57146.17% to -$2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.9 billion, marking a year-over-year decrease of 33524.23%. This contributed to the annual value of -$4.9 billion for FY2025, which is 33524.23% down from last year.
  • Cvs Health's Cash from Financing Activities amounted to -$2.0 billion in Q4 2025, which was down 57146.17% from -$1.4 billion recorded in Q3 2025.
  • In the past 5 years, Cvs Health's Cash from Financing Activities ranged from a high of $3.6 billion in Q2 2023 and a low of -$3.3 billion during Q2 2021
  • Moreover, its 5-year median value for Cash from Financing Activities was -$2.0 billion (2021), whereas its average is -$1.3 billion.
  • As far as peak fluctuations go, Cvs Health's Cash from Financing Activities soared by 24733.85% in 2023, and later tumbled by 57146.17% in 2025.
  • Cvs Health's Cash from Financing Activities (Quarter) stood at -$2.9 billion in 2021, then increased by 24.95% to -$2.2 billion in 2022, then soared by 55.56% to -$972.0 million in 2023, then skyrocketed by 144.34% to $431.0 million in 2024, then plummeted by 571.46% to -$2.0 billion in 2025.
  • Its Cash from Financing Activities was -$2.0 billion in Q4 2025, compared to -$1.4 billion in Q3 2025 and $806.0 million in Q2 2025.